A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma

Launched by SICHUAN CANCER HOSPITAL AND RESEARCH INSTITUTE · Jul 10, 2025

Keywords

ClinConnect Summary

This study is looking at how well and how safely a type of cancer treatment called PD-1 inhibitors works when combined with chemotherapy, with or without radiation, in patients whose nasopharyngeal cancer (a type of cancer that starts in the upper part of the throat) has spread to the lungs. The researchers plan to review past medical records of patients who have already received these treatments to better understand their effects in real-world settings.

Adults aged 18 and older with a confirmed diagnosis of nasopharyngeal cancer that has spread to the lungs or nearby areas may be eligible if their overall health is good enough to handle treatment, and if they have measurable cancer spots visible on scans. People who have not received similar immune-based treatments before and haven’t had other recent cancer therapies might be included. Since this study looks back at past cases, participants won’t be actively treated or followed during the study, but their medical data will be carefully reviewed to learn more about the benefits and risks of this combined treatment approach.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. age of at least 18 years;
• • 2. Karnofsky Performance Status (KPS) ≥60;
• • 3. histologically confirmed nasopharyngeal squamous carcinoma;
• • 4. metastatic disease after primary standard treatment (patients who had metastatic diseases over six months after treatment);
• • 5. at least 1 measurable metastatic lesions in lung or mediastinal or pleura (imaging for distant metastases with FDG-PET/CT or chest/abdomen CT with contrast);
• • 6. adequate renal , liver and bone marrow function.
• Exclusion Criteria:
• • 1. previous treatment with an immune checkpoint inhibitor;
• • 2. recurrent disease;
• • 3. previous systemic chemotherapy for metastatic disease;
• • 4. symptomatic central nervous system metastases;
• • 5. a history of non-infectious pneumonitis that required glucocorticoids, or active autoimmune disease;
• • 6. severe organ dysfunction or not suitable for chemoradiotherapy;
• • 7. individuals that had serious kidney, heart, blood, nervous system, or liver diseases or psychiatric disorders;
• • 8. individuals that had taken part in any other clinical trials testing other drugs within 3 months of the present study;
• • 9. other patients whom researchers deemed unsuitable to participate in the study.